Cd19

CAR-T Fatalities Prompt Pauses at Novartis and BMS

Three patients died in Novartis's CD19-directed CAR-T trials due to a dangerous immune reaction, prompting a halt to those programs, with Bristol Myers Squibb pausing a similar therapy as well.